Systemic and intrathecal effects of a novel series of phospholipase A2 inhibitors on hyperalgesia and spinal prostaglandin E2 release
about
Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic interventionIntracellular phospholipase A(2) group IVA and group VIA play important roles in Wallerian degeneration and axon regeneration after peripheral nerve injury.Inhibition of secreted phospholipases A₂ by 2-oxoamides based on α-amino acids: Synthesis, in vitro evaluation and molecular docking calculations.Analgesic properties of a peripherally acting and GalR2 receptor-preferring galanin analog in inflammatory, neuropathic, and acute pain models.Phospholipase A2 superfamily members play divergent roles after spinal cord injury.Binding conformation of 2-oxoamide inhibitors to group IVA cytosolic phospholipase A2 determined by molecular docking combined with molecular dynamics.p38 MAPK, microglial signaling, and neuropathic pain.A novel monoacylglycerol lipase inhibitor with analgesic and anti-inflammatory activityInhibition of spinal cytosolic phospholipase A(2) expression by an antisense oligonucleotide attenuates tissue injury-induced hyperalgesia.Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes.Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis.Synthesis of 2-oxoamides based on sulfonamide analogs of gamma-amino acids and their activity on phospholipase A2.2-Oxoamide inhibitors of phospholipase A2 activity and cellular arachidonate release based on dipeptides and pseudodipeptidesPhospholipase A2 structure/function, mechanism, and signaling.Location of inhibitors bound to group IVA phospholipase A2 determined by molecular dynamics and deuterium exchange mass spectrometry.Liberating Chiral Lipid Mediators, Inflammatory Enzymes, and LIPID MAPS from Biological Grease.Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymesPhospholipase A2 inhibitors as potential therapeutic agents for the treatment of inflammatory diseases.Respiratory allergies: a general overview of remedies, delivery systems, and the need to progressPhospholipase A2 inhibitors for the treatment of inflammatory diseases: a patent review (2010--present).Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injury-induced cleavage of fractalkine.2-Oxoesters: A Novel Class of Potent and Selective Inhibitors of Cytosolic Group IVA Phospholipase A2.2-Oxoamide inhibitors of cytosolic group IVA phospholipase A2 with reduced lipophilicity.BmPLA2 containing conserved domain WD40 affects the metabolic functions of fat body tissue in silkworm, Bombyx mori.2-Oxoamides based on dipeptides as selective calcium-independent phospholipase A2 inhibitors.Preclinical Analgesic and Safety Evaluation of the GalR2-preferring Analog, NAX 810-2.
P2860
Q26997377-DE0F504C-DA4B-4221-A9D3-0BB128928AE2Q33814817-C99B4B15-B924-42D3-9D3E-08F51E449D84Q34632021-D1B0CFF3-E634-4125-B6C5-F498F5A28828Q34785603-B5B946CA-05C1-4655-A72F-109C5E621447Q35609640-7A260B66-A577-49EB-8100-05F0147099D0Q35691760-EF3CA3C8-3DF5-4A2C-A45B-A2ECEBA1D765Q36345136-741DD40B-0156-430D-A39A-9781DC1DFC7DQ37016733-C362D62F-8019-4C8C-9C77-AA22C04198C5Q37093006-7A652724-613F-4C8B-A27D-4F095E590E62Q37112089-668E637D-EDE7-4AEA-993C-B38C10D3AB03Q37181286-E9ACCD18-0751-4AA4-84C1-D7AA9D3900BDQ37184050-177C4397-7AA7-42B4-B5E1-BC8028CFEB3BQ37226101-70C213AA-66C2-4055-8C8B-4EE6D4C6B972Q37326136-7916A93E-9925-4236-8D2C-647497205972Q37389172-26E9855D-6524-4005-B043-4F012A265FBBQ37421407-F457EBF6-473A-4625-B996-C389EFB59AB1Q37485758-7AFB824C-61FB-47AA-8A48-87FB13E18A37Q37658843-F951BF06-DA8A-404B-B4C9-AC36DE8D8F9AQ37679681-AF778DE8-B2CE-4A89-9821-74A6F4894CA1Q38072094-2862C5B0-59C5-48DC-9888-EA11D510FE00Q40325740-2E61A2A3-34F4-4C05-974D-4B40DBE723F5Q41204206-B93DEC32-3878-4635-AC45-0E5065BA40ECQ41634441-408E26C0-5E07-4688-A572-CDA1A87ECAEFQ42000713-9F7C50A8-2C31-40BF-9F23-175E469AAC0EQ43747404-2364BFF2-15C9-4E30-972E-C502AA0D0138Q52099813-5AF73E84-260B-412C-907C-973389FD78A3
P2860
Systemic and intrathecal effects of a novel series of phospholipase A2 inhibitors on hyperalgesia and spinal prostaglandin E2 release
description
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2006
@ast
im Januar 2006 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2006/01/01)
@sk
vědecký článek publikovaný v roce 2006
@cs
wetenschappelijk artikel (gepubliceerd op 2006/01/01)
@nl
наукова стаття, опублікована в січні 2006
@uk
مقالة علمية (نشرت عام 2006)
@ar
name
Systemic and intrathecal effec ...... pinal prostaglandin E2 release
@ast
Systemic and intrathecal effec ...... pinal prostaglandin E2 release
@en
Systemic and intrathecal effec ...... pinal prostaglandin E2 release
@nl
type
label
Systemic and intrathecal effec ...... pinal prostaglandin E2 release
@ast
Systemic and intrathecal effec ...... pinal prostaglandin E2 release
@en
Systemic and intrathecal effec ...... pinal prostaglandin E2 release
@nl
prefLabel
Systemic and intrathecal effec ...... pinal prostaglandin E2 release
@ast
Systemic and intrathecal effec ...... pinal prostaglandin E2 release
@en
Systemic and intrathecal effec ...... pinal prostaglandin E2 release
@nl
P2093
P356
P1476
Systemic and intrathecal effec ...... pinal prostaglandin E2 release
@en
P2093
Bethany Fitzsimmons
Camilla I. Svensson
Christoforos G. Kokotos
Daren Stephens
Dimitra Hadjipavlou-Litina
George Kokotos
Tony L. Yaksh
Xiao-Ying Hua
P304
P356
10.1124/JPET.105.091686
P407
P577
2006-01-01T00:00:00Z